Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that CEO Alan H. Auerbach will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The virtual presentation starts at 7:00 a.m. EDT on September 12, 2022 and will be available for 30 days on Puma's website. Puma specializes in developing innovative cancer treatments, notably NERLYNX® (neratinib), approved by the FDA for specific breast cancer treatments. More information can be found at Puma's website.
Puma Biotechnology (NASDAQ: PBYI) announced on September 1, 2022, that its Compensation Committee approved inducement restricted stock unit awards for 18,750 shares to two new non-executive employees. These awards are under the 2017 Employment Inducement Incentive Award Plan and will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter. The awards were granted to incentivize new employees as per Nasdaq Listing Rule 5635(c)(4).
Toragen, Inc., a biotechnology firm focused on treating HPV-induced cancers, has announced new board appointments. Mr. Paul Engler, a seasoned investor, joins the Board of Directors, while Cheryl Collett has been appointed CFO effective June 20, 2022. Collett, with over 20 years in finance, previously worked at Puma Biotechnology (NASDAQ: PBYI). Dr. Richard Lumpkin will lead Research & Development starting July 1, 2022. Engler commended Toragen’s team and unique platform, highlighting the company's commitment to addressing HPV-related health issues.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on August 3, 2022, that its Compensation Committee approved inducement restricted stock unit awards for six new non-executive employees, covering 37,250 shares. These awards, granted under the 2017 Employment Inducement Incentive Award Plan, will vest over three years, with one-third vesting on the first anniversary of August 1, 2022, and one-sixth every subsequent six months, contingent on continued service. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported a net income of $9.4 million for Q2 2022, an improvement from a net loss of $5.1 million in Q2 2021. Product revenue reached $51.3 million, up from $48.9 million year-over-year. However, total revenue for the first half of 2022 decreased to $105.3 million compared to $151.6 million in the same period of 2021. Operating expenses significantly reduced from $148.1 million to $94.0 million year-over-year. Cash and equivalents fell to $60.8 million from $82.1 million as of December 2021. Puma aims to enhance access to its cancer drug NERLYNX and plans to report further clinical trial data in H2 2022.
Puma Biotechnology, Inc. (NASDAQ: PBYI) will host a conference call on August 4, 2022, at 1:30 p.m. PDT to discuss its second quarter 2022 financial results. Access is available by dialing (877) 709-8150 domestically or (201) 689-8354 internationally. The call will also be webcast live on Puma's website, with a 90-day replay available post-event. The company focuses on developing innovative cancer care products, notably its approved drug NERLYNX® (neratinib), for treating HER2-positive breast cancer.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on July 1, 2022, that its Compensation Committee granted inducement restricted stock unit awards for 30,875 shares to six new non-executive employees. The awards, part of the 2017 Employment Inducement Incentive Award Plan, vest over three years, with the first third vesting on July 1, 2023. These grants were made to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). Puma is focused on developing innovative products for cancer care, with its primary product, NERLYNX® (neratinib), approved for specific breast cancer treatments.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on June 3, 2022, the granting of inducement restricted stock unit awards covering 38,125 shares to six new non-executive employees. These awards, part of the 2017 Employment Inducement Incentive Award Plan, vest over three years. One-third will vest on the first anniversary of the June 1, 2022, commencement date, with subsequent vesting every six months. This inducement is compliant with Nasdaq Listing Rule 5635(c)(4). Puma is focused on innovative cancer care products, including NERLYNX, approved for HER2-positive breast cancer treatment.
Puma Biotechnology (NASDAQ: PBYI) presented Phase II SUMMIT trial results at ASCO, highlighting the efficacy of neratinib, fulvestrant, and trastuzumab in hormone receptor-positive, HER2-negative, HER2-mutant metastatic breast cancer. The trial showed a 35.3% objective response rate and 41.7% clinical benefit rate among patients previously treated with CDK4/6 inhibitors. The combination therapy led to a median progression-free survival of 8.2 months, indicating its potential for durable responses across various HER2 mutations.
Puma Biotechnology, Inc. (NASDAQ: PBYI) presented final results from the Phase II SUMMIT ‘basket’ trial for neratinib at the 2022 ASCO Annual Meeting. The trial focused on treatment-refractory patients with metastatic biliary tract cancers harboring somatic HER2 mutations. Out of 25 patients, the overall response rate was 16%, with a median progression-free survival of 2.8 months and overall survival of 5.4 months. Diarrhea was the most common toxicity observed (56%). While neratinib shows potential, further studies are needed for improved treatment strategies.